SEC Filing Summary: Xenomics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenomics, Inc. (not Cardiff Oncology, Inc.) on July 7, 2006, covering events occurring on June 30, 2006. The company is incorporated in Florida and maintains its principal executive offices in New York, New York.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance data.
Material Changes
On June 30, 2006, Xenomics, Inc. terminated a Technology Acquisition Agreement dated June 24, 2004. The agreement was between the Company and its wholly-owned subsidiary, Xenomics, L. David Tomei (Co-Chairman and CEO), Samuil Umansky (President), Hovsep Melkonyan (VP, Research), Kathryn Wilkie, and Anatoly Lichtenstein. The agreement provided these parties with the option to acquire the Company's core technology under certain conditions. The termination was executed because circumstances rendered the probability of such an acquisition extremely remote.
Outlook, Risks, and Management Commentary
Management commentary is limited to the rationale for the termination: the likelihood of the technology acquisition by the specified individuals is now considered extremely remote. No forward-looking guidance, new risks, or contingencies were disclosed in this specific filing.
Investor Verification Checklist
- Verify the identity of the registrant as Xenomics, Inc., distinct from Cardiff Oncology, Inc.
- Confirm the status of the Company's core technology following the termination of the acquisition option.
- Review the "Agreement of Termination and Release" (Exhibit 10.1) for any potential release of claims or liabilities.
- Check subsequent filings for any financial impact resulting from this termination.